Q-omics provides the consensus-scored ZNF689 profile across patient tissues and cancer cell-line models. ZNF689 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF689 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF689 RNA expression shows 20,128 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ZNF689 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF689 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF689 survival associations across molecular data types. ZNF689 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF689 RNA expression–survival associations across cancer types. High ZNF689 expression shows unfavorable associations in UVM, but favorable associations in KIRC, BRCA, HNSC, ACC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF689 RNA expression.
This table summarizes ZNF689 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF689. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF689 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, LIHC, STAD and COAD. The THCA box plot shows higher ZNF689 RNA expression in normal versus tumor tissue (log2 FC = −0.851, t-test p < 0.001).
This table shows molecular features associated with ZNF689 in patient tissues and cancer cell lines. In patient samples, ZNF689 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF689 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
